GT Biopharma, Inc.
GTBP
$2.35
$0.062.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.78M | -3.41M | -3.71M | -2.27M | -2.96M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 77.00K | -93.00K | 27.00K | -528.00K | 461.00K |
| Change in Net Operating Assets | 1.23M | 767.00K | 147.00K | -1.37M | 454.00K |
| Cash from Operations | -2.47M | -2.74M | -3.54M | -4.16M | -2.05M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.00K | -1.00K | 7.86M | 5.03M | 478.00K |
| Cash from Investing | 1.00K | -1.00K | 7.86M | 5.03M | 478.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 2.98M | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 0.00 | 2.98M | -- | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.47M | -2.74M | 7.30M | 871.00K | -1.57M |